Cargando…
Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070610/ https://www.ncbi.nlm.nih.gov/pubmed/33921547 http://dx.doi.org/10.3390/ijerph18084071 |
_version_ | 1783683510398091264 |
---|---|
author | Usmanova, Ruzilya Parpieva, Nargiza Davtyan, Hayk Denisiuk, Olga Gadoev, Jamshid Alaverdyan, Sevak Dumchev, Kostyantyn Liverko, Irina Abdusamatova, Barno |
author_facet | Usmanova, Ruzilya Parpieva, Nargiza Davtyan, Hayk Denisiuk, Olga Gadoev, Jamshid Alaverdyan, Sevak Dumchev, Kostyantyn Liverko, Irina Abdusamatova, Barno |
author_sort | Usmanova, Ruzilya |
collection | PubMed |
description | Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug dosages used, and documentation of treatment changes (such as prolongation of intensive phase, change of drugs, and their reasons) in the treatment card and Consilium form. A total of 1481 patients were included. Of them, only 25% received standardized regimens as per guidelines and the remaining received individualized regimens. There was an increasing trend in using standardized regimens from 2% in 2012 to 44% in 2018. Compliance to recommended weight-based drug dosages was observed in 85% of the patients during the intensive phase and 84% in the continuation phase—ranged 71–91% over the years. Prolongation of the intensive phase was done in 42% of patients. The treatment was changed in 44% of patients during the intensive phase and 34% of patients during the continuation phase. The documentation of treatment changes was suboptimal (42–75%) during the initial years (2012–2014); however, it improved significantly during later years (86–100%). Future research should explore reasons for non-compliance so that the quality of patient care can be improved. |
format | Online Article Text |
id | pubmed-8070610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80706102021-04-26 Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? Usmanova, Ruzilya Parpieva, Nargiza Davtyan, Hayk Denisiuk, Olga Gadoev, Jamshid Alaverdyan, Sevak Dumchev, Kostyantyn Liverko, Irina Abdusamatova, Barno Int J Environ Res Public Health Article Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug dosages used, and documentation of treatment changes (such as prolongation of intensive phase, change of drugs, and their reasons) in the treatment card and Consilium form. A total of 1481 patients were included. Of them, only 25% received standardized regimens as per guidelines and the remaining received individualized regimens. There was an increasing trend in using standardized regimens from 2% in 2012 to 44% in 2018. Compliance to recommended weight-based drug dosages was observed in 85% of the patients during the intensive phase and 84% in the continuation phase—ranged 71–91% over the years. Prolongation of the intensive phase was done in 42% of patients. The treatment was changed in 44% of patients during the intensive phase and 34% of patients during the continuation phase. The documentation of treatment changes was suboptimal (42–75%) during the initial years (2012–2014); however, it improved significantly during later years (86–100%). Future research should explore reasons for non-compliance so that the quality of patient care can be improved. MDPI 2021-04-12 /pmc/articles/PMC8070610/ /pubmed/33921547 http://dx.doi.org/10.3390/ijerph18084071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Usmanova, Ruzilya Parpieva, Nargiza Davtyan, Hayk Denisiuk, Olga Gadoev, Jamshid Alaverdyan, Sevak Dumchev, Kostyantyn Liverko, Irina Abdusamatova, Barno Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title | Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title_full | Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title_fullStr | Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title_full_unstemmed | Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title_short | Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy? |
title_sort | treatment compliance of multidrug resistant tuberculosis in uzbekistan: does practice follow policy? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070610/ https://www.ncbi.nlm.nih.gov/pubmed/33921547 http://dx.doi.org/10.3390/ijerph18084071 |
work_keys_str_mv | AT usmanovaruzilya treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT parpievanargiza treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT davtyanhayk treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT denisiukolga treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT gadoevjamshid treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT alaverdyansevak treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT dumchevkostyantyn treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT liverkoirina treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy AT abdusamatovabarno treatmentcomplianceofmultidrugresistanttuberculosisinuzbekistandoespracticefollowpolicy |